• Something wrong with this record ?

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults

WH. Jost, P. Kaňovský, MA. Hast, A. Hanschmann, M. Althaus, AT. Patel

. 2023 ; 15 (6) : . [pub] 20230523

Language English Country Switzerland

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23011388

The pooled incidences of treatment-emergent adverse events (TEAEs) were examined by indication using the integrated clinical database of Merz-sponsored, placebo-controlled, or repeat-dose studies of incobotulinumtoxinA in adults with cervical dystonia, blepharospasm, limb spasticity, sialorrhea, or essential tremor of the upper limb. Overall incidences of TEAEs, serious TEAEs, TEAEs leading to discontinuation, fatal TEAEs, TEAEs of special interest (TEAESIs; indicating possible toxin spread), and treatment-related (TR) events were determined for incobotulinumtoxinA and placebo after a single injection and for repeated dose cycles of incobotulinumtoxinA. The most frequent events after a single dose of incobotulinumtoxinA are summarized. After a single cycle, incidences of overall TEAEs were similar between incobotulinumtoxinA and the placebo in most indications, although between-indication differences were observed. Few TEAEs led to incobotulinumtoxinA discontinuation; there were no fatal TEAEs with incobotulinumtoxinA. In general, repeated cycles did not increase the incidence of any event. The most frequent TR-TEAEs were indication-dependent, including dysphagia for indications affecting the head or neck. The TR-TEAESIs across all indications were most commonly muscular weakness, dysphagia and dry mouth. Overall, the results of this pooled analysis support and extend the favorable safety and tolerability profile of incobotulinumtoxinA for the treatment of adult neurological disorders established by individual clinical studies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23011388
003      
CZ-PrNML
005      
20230801133021.0
007      
ta
008      
230718s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/toxins15060353 $2 doi
035    __
$a (PubMed)37368654
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Jost, Wolfgang H $u Parkinson-Klinik Ortenau, 77709 Wolfach, Germany $1 https://orcid.org/0000000285743297 $7 xx0060832
245    10
$a Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults / $c WH. Jost, P. Kaňovský, MA. Hast, A. Hanschmann, M. Althaus, AT. Patel
520    9_
$a The pooled incidences of treatment-emergent adverse events (TEAEs) were examined by indication using the integrated clinical database of Merz-sponsored, placebo-controlled, or repeat-dose studies of incobotulinumtoxinA in adults with cervical dystonia, blepharospasm, limb spasticity, sialorrhea, or essential tremor of the upper limb. Overall incidences of TEAEs, serious TEAEs, TEAEs leading to discontinuation, fatal TEAEs, TEAEs of special interest (TEAESIs; indicating possible toxin spread), and treatment-related (TR) events were determined for incobotulinumtoxinA and placebo after a single injection and for repeated dose cycles of incobotulinumtoxinA. The most frequent events after a single dose of incobotulinumtoxinA are summarized. After a single cycle, incidences of overall TEAEs were similar between incobotulinumtoxinA and the placebo in most indications, although between-indication differences were observed. Few TEAEs led to incobotulinumtoxinA discontinuation; there were no fatal TEAEs with incobotulinumtoxinA. In general, repeated cycles did not increase the incidence of any event. The most frequent TR-TEAEs were indication-dependent, including dysphagia for indications affecting the head or neck. The TR-TEAESIs across all indications were most commonly muscular weakness, dysphagia and dry mouth. Overall, the results of this pooled analysis support and extend the favorable safety and tolerability profile of incobotulinumtoxinA for the treatment of adult neurological disorders established by individual clinical studies.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    12
$a botulotoxiny typu A $x škodlivé účinky $7 D019274
650    12
$a poruchy polykání $x farmakoterapie $7 D003680
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a nemoci nervového systému $x farmakoterapie $7 D009422
650    12
$a nervosvalové látky $x škodlivé účinky $7 D009465
650    12
$a tortikolis $x farmakoterapie $7 D014103
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kaňovský, Petr $u Faculty of Medicine and Dentistry and University Hospital, Palacký University Olomouc, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000290093241 $7 jn20000620150
700    1_
$a Hast, Michael A $u Merz Pharmaceuticals, LLC, Raleigh, NC 27615, USA
700    1_
$a Hanschmann, Angelika $u Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany
700    1_
$a Althaus, Michael $u Merz Therapeutics GmbH, 60318 Frankfurt am Main, Germany
700    1_
$a Patel, Atul T $u Kansas City Bone and Joint Clinic, Overland Park, KS 66211, USA $1 https://orcid.org/0000000327657953
773    0_
$w MED00177194 $t Toxins $x 2072-6651 $g Roč. 15, č. 6 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37368654 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801133017 $b ABA008
999    __
$a ok $b bmc $g 1963670 $s 1197653
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 15 $c 6 $e 20230523 $i 2072-6651 $m Toxins $n Toxins $x MED00177194
LZP    __
$a Pubmed-20230718

Find record

Citation metrics

Archiving options